Licia Totani1, Antonio Piccoli1, Giuseppe Dell'Elba1, Amore Concetta1, Angelomaria Di Santo1, Nicola Martelli1, Lorenzo Federico1, Zehra Pamuklar1, Susan S Smyth1, Virgilio Evangelista2. 1. From the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.). 2. From the Department of Translational Pharmacology, Laboratory of Vascular Biology and Pharmacology, Fondazione Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy (L.T., A.P., G.D., A.C., A.D.S., N.M., V.E.); Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY (L.F., Z.P., S.S.S.); and VA Medical Center, Lexington, KY (S.S.S.). evangelista@negrisud.it.
Abstract
OBJECTIVE: Platelet-neutrophil interactions play a key role in cardiovascular disease and inflammatory processes. Src family kinases mediate P-selectin glycoprotein ligand-1-Mac-1 cross talk necessary for firm platelet-neutrophil adhesion. Because Src family kinase activity can be regulated by cAMP-dependent pathways, in this work, we evaluated the role of phosphodiesterases in the signaling events that are required to sustain platelet-neutrophil interactions and neutrophil recruitment at the site of vascular injury. APPROACH AND RESULTS: In neutrophils exposed to P-selectin, selective phosphodiesterase 4 (PDE4) inhibition prevented Src family kinase-mediated phosphorylation of the proline-rich tyrosine kinase 2 on Tyr579/Tyr580. The effects of PDE4 inhibition required protein kinase A, likely through protein kinase A-mediated activation of COOH-terminal Src kinase, a major negative regulator of Src family kinases. PDE4, but not other phosphodiesterase inhibitors, reduced platelet-neutrophil conjugates as well as neutrophil firm adhesion on spread platelets under flow conditions. The effect of PDE4 inhibition on neutrophil adhesion was primarily mediated by downregulation of P-selectin-induced activation of Mac-1. In a murine model of endovascular injury, selective inhibition of PDE4 significantly reduced neutrophil recruitment at the site of vascular damage. CONCLUSIONS: This study identifies PDE4 as a central node in the signaling network that mediates platelet-neutrophil adhesion and suggests that pharmacological inhibition of PDE4 may represent a novel therapeutic avenue for the treatment of cardiovascular disease.
OBJECTIVE: Platelet-neutrophil interactions play a key role in cardiovascular disease and inflammatory processes. Src family kinases mediate P-selectin glycoprotein ligand-1-Mac-1 cross talk necessary for firm platelet-neutrophil adhesion. Because Src family kinase activity can be regulated by cAMP-dependent pathways, in this work, we evaluated the role of phosphodiesterases in the signaling events that are required to sustain platelet-neutrophil interactions and neutrophil recruitment at the site of vascular injury. APPROACH AND RESULTS: In neutrophils exposed to P-selectin, selective phosphodiesterase 4 (PDE4) inhibition prevented Src family kinase-mediated phosphorylation of the proline-rich tyrosine kinase 2 on Tyr579/Tyr580. The effects of PDE4 inhibition required protein kinase A, likely through protein kinase A-mediated activation of COOH-terminal Src kinase, a major negative regulator of Src family kinases. PDE4, but not other phosphodiesterase inhibitors, reduced platelet-neutrophil conjugates as well as neutrophil firm adhesion on spread platelets under flow conditions. The effect of PDE4 inhibition on neutrophil adhesion was primarily mediated by downregulation of P-selectin-induced activation of Mac-1. In a murine model of endovascular injury, selective inhibition of PDE4 significantly reduced neutrophil recruitment at the site of vascular damage. CONCLUSIONS: This study identifies PDE4 as a central node in the signaling network that mediates platelet-neutrophil adhesion and suggests that pharmacological inhibition of PDE4 may represent a novel therapeutic avenue for the treatment of cardiovascular disease.
Authors: P Piccardoni; R Sideri; S Manarini; A Piccoli; N Martelli; G de Gaetano; C Cerletti; V Evangelista Journal: Blood Date: 2001-07-01 Impact factor: 22.113
Authors: William B White; Glen E Cooke; Peter R Kowey; Peter M A Calverley; Dirk Bredenbröker; Udo-Michael Goehring; Haiyuan Zhu; Hassan Lakkis; Hans Mosberg; Paul Rowe; Klaus F Rabe Journal: Chest Date: 2013-09 Impact factor: 9.410
Authors: María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo Journal: Br J Pharmacol Date: 2002-04 Impact factor: 8.739
Authors: M I Furman; M R Barnard; L A Krueger; M L Fox; E A Shilale; D M Lessard; P Marchese; A L Frelinger; R J Goldberg; A D Michelson Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: T Vang; K M Torgersen; V Sundvold; M Saxena; F O Levy; B S Skålhegg; V Hansson; T Mustelin; K Taskén Journal: J Exp Med Date: 2001-02-19 Impact factor: 14.307
Authors: Achim Obergfell; Koji Eto; Attila Mocsai; Charito Buensuceso; Sheri L Moores; Joan S Brugge; Clifford A Lowell; Sanford J Shattil Journal: J Cell Biol Date: 2002-04-08 Impact factor: 10.539
Authors: Saray Varona; Lídia Puertas; María Galán; Mar Orriols; Laia Cañes; Silvia Aguiló; Mercedes Camacho; Marc Sirvent; Vicente Andrés; José Martínez-González; Cristina Rodríguez Journal: Antioxidants (Basel) Date: 2021-03-16